history of glp 1 agonists glp-1 A timeline of GLP- discovery and clinical development. Created in GLP-1R Agonists for Weight Loss

GLP-1 Targeted Peptide Weight Loss Drugs Market Share, by Dosage Strength, 20242034 Figure 5: U.S

57 , R93r108 (2016)

Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed obesity management, offering substantial weight loss and metabolic benefits

The main liver isoform, THR-b, enhances hepatic fatty acid oxidation and lowers steatosis and hyperlipidemia in animal models, whereas THR-a is important in cardiac function

Measures Past-year use of GLP-1 receptor agonists and GLP-1/GIP compounds (i.e

Longer-term metabolic benefits, including effects on body composition and insulin sensitivity, typically emerge over months of consistent daily consumption, consistent with the timeframes seen in trials like PREDIMED (median follow-up of 4.8 years)